Miguel Garcia-Pardo, MD, Princess Margaret Cancer Center, Toronto, Canada, discusses liquid biopsy to detect molecular alterations in plasma. He discusses results from an investigation into the time to treatment in patients suspected of lung cancer who received liquid biopsy compared to data from patients who had tissue biopsies. Time to treatment was significantly reduced in the liquid biopsy cohort compared to tissue biopsy and liquid biopsy accurately detected NSCLC in 60% of the study subjects.